- **1** Access to medicines for the treatment of chronic diseases
- 2 in Chile: qualitative analysis of perceived patient
- 3 barriers and facilitators in five regions of the country
- 4

5 Short title

6 Access to medicines in Chile: qualitative analysis of

7 perceived barriers and facilitators

8

9 Authors

- 10 Carla Castillo Laborde¹, Isabel Matute¹, Ximena Sgombich^{2&}, Daniel Jofré^{2&}
- ¹¹ Center for Epidemiology and Health Policy, Faculty of Medicine Clínica Alemana,
- 12 Universidad del Desarrollo.
- ¹³ ² Nous Communication and Strategy.
- 14
- 15 * Corresponding Author
- 16 Isabel Matute
- 17 E-mail: mimatute@udd.cl

18

19 [¶] These authors contributed equally to this work.

- 20 [&] These authors also contributed equally to this work.
- . .

44 Abstract

45 Purpose: To know patients' perceptions of barriers and facilitators in access to medicines in 46 general, and those associated with the treatment of three chronic conditions of high 47 prevalence in Chile: diabetes, dyslipidemia and hypertension. Methods: Ten focus groups of 48 patients with these diseases, diagnosed for at least six months and prescribed medication, 49 were included. These were carried out in five regions of Chile: Arica, in the north, Aysén, in 50 the south, and Valparaíso, Metropolitan, and Maule, in the central zone. The criteria for the 51 formation of groups were region, age, health system (public or private) and socioeconomic 52 level (residence commune). Sessions were recorded, transcribed, and analyzed by categories. 53 Results: The experience of access to medicines is determined by the insurance system, the 54 experience of care with public or private providers, and geographical-administrative 55 difference between capital and other regions. Beneficiaries of public sector, despite their 56 greater socioeconomic vulnerability, perceive greater protection in access: access conditions, 57 delivery reliability and adherence to pharmacological treatment are met. The main problem 58 observed is the financing of treatments not covered by the health system. Policyholders in 59 private sector perceive that they have access to medicines of better quality than those 60 provided free of charge by public sector, but raise fears associated with the inability to afford 61 them and distrust in the process, linked to alliances between laboratories and physicians. 62 Public sector beneficiaries value territorial coverage of primary care, which guarantees 63 access in isolated areas. Regarding the type of provider, public sector shows greater capacity 64 for user loyalty, which is expressed in regular visits and follow-up; unlike discontinuous 65 examinations among private sector beneficiaries. Conclusions: Different access conditions

66	both at the territorial level and in the health subsystems are evident. It is necessary to make
67	progress in addressing the problem of access to medicines in a comprehensive manner.
68	

- 69 **Keywords:** barriers; facilitators; access: medicines: segmentation: qualitative: Chile.
- 70

71 Introduction

72 Medications are one of the most widely used therapeutic tools in medicine: therefore, 73 access is a challenge for health systems. Access to health services, and in this case to 74 medicines, is understood as the opportunity for people to reach and obtain the appropriate 75 services in situations of need (1), i.e., it implies a process that goes from the need for a 76 medication, to its use by the patient (2). Access is a multidimensional concept, which includes 77 availability, acceptability and geographic and financial accessibility as its most important 78 dimensions (3,4). In other words, access to medicines implies their availability at a 79 reasonable distance, their acceptance by patients and physicians and the real possibility of 80 financing. These dimensions, as well as multiple barriers and facilitators associated with each 81 of them, were also identified globally by a scope review on medications associated with three 82 chronic conditions of high prevalence (5), finding that the most reported dimension, in 83 countries of all regions and income levels, is affordability, and among the most relevant 84 barriers, the availability of medications, long distances, cost, professional support and 85 cultural aspects (5).

86

87 Despite the therapeutic importance of pharmaceutical drugs, the lack of access to 88 essential medicines, defined as those that meet the priority health care needs of the

population, is one of the most serious public health problems globally, affecting one third of
the world's population, with consequences for loss of life and deterioration of health (6).

91

92 In Chile, more than 57% of those over 15 years of age consume at least one 93 medication, with paracetamol and acetyl salicylic acid being the most consumed nationwide, 94 followed by losartan, metformin and atorvastatin (7). Of those with a health condition who 95 receive medical care, 7.4% of people report having problems related to the delivery of 96 medications to the health facility or access to them due to their cost (8). Medications represent the most important item of out-of-pocket spending on health (9); in fact, it is estimated that 97 98 30% of Chileans have stopped buying medications or stopped their treatments because they 99 cannot afford them (10,11).

100

101 In the case of Chile, there is the public subsystem (FONASA beneficiaries), the 102 private one (ISAPRE beneficiaries), and that of the Armed Forces, presenting a marked 103 selection of risks, which leaves FONASA, for the most part, with the most vulnerable and 104 needy population, and ISAPRE with the richest and healthiest population (12). There are 105 vertical programs associated with certain diseases or conditions (13); that is, if we consider 106 the conditions associated with the most consumed pharmaceutical drugs 107 (losartan/hypertension, metformin/diabetes, atorvastatin/dyslipidemia), we can identify 108 explicit guarantees (GES or AUGE) of access, opportunity, financial protection and quality 109 for diabetes and hypertension, both for the beneficiaries of FONASA and those of ISAPRE 110 (free delivery in the case of the former, and with a limited copayment established by law for 111 the latter) (14), and we also identify a program called the Pharmacy Fund (FOFAR), for the 112 FONASA beneficiaries, which ensures the availability (and free delivery) of medicines

113 associated precisely with diabetes, hypertension and dyslipidemia in primary health care 114 facilities (15). Thus, the way in which Chileans access their medicines depends, among 115 others, on the subsystem to which they belong and the health condition from which they 116 suffer. 117 118 In the context described above, the present study aimed to know the patients' 119 perceptions of the barriers and facilitators in access to medicines in general, and in particular 120 regarding those associated with the treatment of three chronic conditions of high prevalence: 121 diabetes, dyslipidemia and hypertension. 122 **Materials and Methods** 123 124 **Participants and context** 125 126 Ten focus groups were held between January and March 2021 in 5 regions of Chile: 127 Arica and Parinacota (one) in the north, Aysén (one) in the south, and Valparaíso (one), 128 Metropolitan (five) and Maule (two) in the central area. 129 130 The composition of the groups was defined according to: region, sex (both), age (45-131 64 and over 65 years), health care system (FONASA and ISAPRE) and socioeconomic level 132 of the municipality of residence (% multidimensional poverty) (16). In addition, the 133 following inclusion criteria were considered: people diagnosed with diabetes, dyslipidemia 134 or hypertension, with prescribed pharmacological treatment, treated in public or private 135 facilities. 6

1	3	6
-	~	v

137	The contact and enrollment process was carried out by a specialized team, identifying		
138	the potential participants, who met the profile required for each group, through community		
139	networks, delivering an invitation to participate in person, and subsequently re-contacting by		
140	phone to answer questions and confirm availability.		
141			
142	The meetings were held in hotel meeting rooms specifically hired for these purposes		
143	and in community centers. All focus groups were in person, so, in consideration of the		
144	COVID-19 Pandemic, demanding prevention protocols were observed.		
145			
146	The focus group participants did so voluntarily and accepted the conditions for		
147	carrying out the activity, which was formalized with the signing of an informed consent. This		
148	study is part of the FONIS Project SA19 0174, which was approved by the Bioethics		
149	Committee of the Faculty of Medicine of Clínica Alemana, Universidad del Desarrollo.		
150			
151	Each session was recorded and transcribed for further analysis.		
152			
153	Data Analysis		
154			
155	To address the set objective, three dimensions of inquiry were considered:		
156			
157	1. General perception of access to health.		
158	2. Access to medicines, from five dimensions of access (3–5):		

159	• Availability: related to the physical existence of medicines,
160	• Geographical accessibility: geographical distance between medicines and location
161	of users who need them,
162	• Affordability: the relationship between the price of medicines and the patients'
163	ability to pay,
164	• Acceptability: acceptance of medicines by the population or social groups and
165	factors that increase or decrease the likelihood of their use; including users'
166	attitudes towards suppliers and medicines, and suppliers' attitudes towards user
167	characteristics,
168	• Adaptation: the relationship between how resources are allocated to deliver
169	medicines to users and their ability to adapt.
170	
171	3. Access barriers and facilitators. Barriers understood as factors that hinder the target
172	population from obtaining and making appropriate use of the medications it requires; and
173	facilitators as factors that help the target population make use of them.
174	
175	The thematic analysis considered an initial stage of familiarization with the data, from
176	the reading of the transcriptions and initial notes. Subsequently, initial categories or codes
177	were established, oriented to the three dimensions mentioned above. A search for topics or
178	reduction of information was carried out based on structuring topics related to the problem
179	investigated. Subsequently, the topics were reviewed, based on a process of re-coding and
180	conceptual delimitation with the support of the Atlas Software.ti 9 (17). Finally, the topics

181 were definitively identified, and a logic tree of topics and subtopics was created.

1	82	
	~	

183	Additionally, empathy maps (18) were prepared to outline and characterize types of
184	users in relation to access to medicines, based on the health care subsystem.
185	

186 **Results**

187

The presentation of the results is divided into three subsections: 1) Description of the participants; 2) General perceptions on access to health, and the barriers and facilitators depending on the dimensions of access (3–5); and 3) the differences between the perceptions of the FONASA and ISAPRE beneficiaries regarding access to medicines.

192

193 Participant Characteristics

194

In total, for the 10 group interviews, 73 interviewees participated, mostly women (61.6%), FONASA beneficiaries (65.8%), with an average age of 60.2 years. In geographical terms, almost half of those interviewed belonged to the Metropolitan Region, followed by 22% in Maule (and rural area), and about 10% in the rest of the regions. Finally, 42.5% of the interviewees resided in communes with a high percentage of multidimensional poverty (Table 1).

201

202

Table 1. Participant Characteristics (n=73)

Average age (min - max)

60.2 (45 - 83)

Sex

203

204

205

Female	61.6%
Male	38.4%
Health subsystem	
FONASA (public)	65.8%
ISAPRE (private)	34.2%
Region	
Arica y Parinacota (Arica city)	9.6%
Aysén (Coyhaique city)	9.6%
Maule (Pelarco city)	21.9%
Metropolitan (Cerro Navia, Las Condes, Providencia, San Mig	guel,
Vitacura)	49.3%
Valparaíso (Viña del Mar city)	9.6%
Zone	
Urban	78.1%
Rural	21.9%
Multidimensional poverty in the commune of residence*	
Low (<10%)	27.4%
Medium (>10% and <20%)	30.1%
High (>20%)	42.5%
Source Prepared by author.	
*Based on (16).	

206 Access dimensions

2	n	
L	υ	1

208	Below is a summary of the findings on the five access dimensions presented in the
209	previous section (availability, geographical accessibility, affordability, acceptability,
210	adaptation), within which, where possible, they are analyzed in terms of three cross-cutting
211	axes identified as markers of the experience of access to medicines: the insurance system; ii)
212	the experience of care with public and private providers; iii) and the geographical differences
213	(Metropolitan Region/other regions; urban/rural) and other regions.
214	
215	Availability
216	
217	In general terms, for the medicines associated with the three conditions of interest, no
218	stock shortages are identified in the case of FONASA beneficiaries, although sometimes brief
219	delays are observed.
220	
221	"Moderator: Have you been told that the clinic pharmacy has no stock of
222	medications?
223	All: No.
224	Woman (W): Every month we have a day.
225	Moderator: So how difficult is it for you to access these medications?
226	Man (M): It's easy for me.
227	W: No, it's not difficult.
228	Moderator: And has the current pandemic situation affected access to medicines?

229	All: No.
230	M: On the contrary, it has been become more streamlined." (FG Arica, mixed,
231	FONASA, 45-65 years old)
232	
233	"W: There are medicines that are sometimes missing, just have to wait
234	W: Wait until they arrive, no longer than a week." (FG Coyhaique, mixed, FONASA,
235	45 to 65 years old)
236	
237	However, the scenario changes when it comes to other health conditions that are more
238	complex. In these cases, stock shortages are reported, rarely, which force people to buy in
239	retail pharmacies.
240	
241	"Moderator: So why do you sometimes have to buy them at the pharmacy and not at
242	the clinic?
243	W: When they do not arrive.
244	W: For the problem I have in my spine, I must take an anti-inflammatory, and they
245	don't stock it, only Tramadol and Tramadol hurts me, because I have heart
246	problems." (FG Cerro Navia, mixed, FONASA, 45 to 65 years old)
247	
248	Geographical accessibility
249	
250	In the case of FONASA beneficiaries, the large extension and distribution throughout
251	the national territory of the primary health care network, through which access is preferential,

252	and which was reinforced by the delivery of medicines to homes during the pandemic, is
253	noteworthy.
254	
255	"Moderator: Who had their medications delivered to them during the pandemic?
256	All: I did.
257	Moderator: Don Juan, explain a little bit about that, before the pandemic, did they
258	deliver medicines or not?
259	M: No.
260	M: Then, they began to deliver medications during the pandemic, and later in the
261	clinic, they said it is a good idea for people over 65 years old.
262	W: Until December that happened in my case. I had to go again in January." (FG
263	Coyhaique, mixed, FONASA, 45 to 65 years old)
264	
265	In the case of ISAPRE beneficiaries, access to medicines is preferably through retail
266	pharmacies and, in recent years, through popular pharmacies (which emerged, in 2015, in the
267	municipal context, and which have access to lower prices because they buy through the
268	National Supply Center - CENABAST, like public sector facilities) (19).
269	
270	"M: I buy in pharmacies, but also my wife, who is very much a "go-getter," signed
271	up in the Vitacura pharmacy, and there we buy it in the Vitabotica. We buy it at half
272	price, less than half price. The truth is super convenient and the other.
273	M: Which one?
274	W: The Vitabotica.
275	M: La Vitabotica". (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65 years old)

People living in rural areas have some difficulties in accessing their medicines, especially

2	7	6
L	1	0

278	due to periodicity, cost and travel time to clinics.
279	
280	"M: Of course it is complicated for me, because in this time that we are with last
281	week that we were quarantined, many times I could not even come to church, because
282	as I say, I am putting a lock on the gate, the bus and collective taxis pass by me,
283	because they come full from Talca. I live in a rural area near her, but it's different,
284	because she has a car" (FG Pelarco, mixed, FONASA, over 65 years old)
285	
286	The older adults, meanwhile, express and demand the need for prioritized care in
287	retail.
288	
289	"M: From the beginning I wanted to make a clarification, there could be a difference
290	in the pharmacies of the older adults, that is, when you go to the pharmacy today,
291	there are 20 people in front of you, that is, it is easy to be 45 minutes in a line, and
292	more, and I could, at least with an identity card, tell you, Hey, I'm an older adult and
293	don't make me wait 45 minutes." (FG Providencia – Las Condes- San Miguel, mixed,
294	ISAPRE, over 65 years old)
295	
296	Affordability
297	

298	In the case of FONASA beneficiaries, there is recognition and assessment of free
299	access to medicines associated with the three conditions of interest.
300	
301	"Moderator: And have any of you stopped taking medication because you couldn't
302	afford it?
303	All: No.
304	Moderator: And yours is accessible. How much do you spend on diabetes,
305	hypertension and cholesterol triglyceride medications?
306	M: I don't spend anything
307	W: Me neither.
308	M: They give us all the medications.
309	W: Sure, they give them. (FG Arica, mixed, FONASA, 45 to 65 years old)
310	
311	"W: Here the one who has money treats the disease he has, and we have to go here
312	to the polyclinic that is the closest, and we do not have money to pay the expenses of
313	the medicine we need, that's why here in Chile it is bad, very bad "(FG Pelarco,
314	mixed, FONASA, 45 to 65 years old)
315	
316	On the other hand, the FONASA user accesses a restricted set of medications
317	(prioritized for coverage) that does not necessarily cover all their health problems. Those
318	health problems whose medicines cannot be afforded are left unattended or partially resolved.
319	This situation is rare when it comes to hypertension, dyslipidemia and diabetes, but it is

320 observed in the management of side effects and in the management of other more complex

321 diseases.

323	W: But later I started to feel well without a problem, but I had to stop buying them if
324	I couldn't afford it, a box with 12 pills cost me \$ 57,000. Then I could not do it, it was
325	day-to-day that I continued with the polyclinic, but they lowered the dose and healed
326	me of my ulcers, and I continue with my medicine from the polyclinic, I will have to
327	continue because I do not have the resources to buy a medication of 50 and so
328	thousand every month. " (FG Coyhaique, mixed, FONASA, 45 to 65 years old)
329	
330	"W: I think so, because, because, for example, here in the clinic they tell you
331	Metformin and you get Metformin, but if you go to the market, to the pharmacies, it
332	is called Hipoglucin, and that medication is so coated that it does not produce the
333	effects that Metformin produces.
334	W: Yes.
335	W: Because of the stomach." (FG Cerro Navia, mixed, FONASA, 45 to 65 years old)
336	
337	The GES/AUGE corresponds to a policy that, among others, allows to reduce the
338	economic burden linked to the treatment of diseases such as diabetes and hypertension.
339	Paradoxically, people do not always associate free medicines with this public policy, that is,
340	their direct consequences (availability of medicines) are known but their origin in the GES
341	(or in FOFAR, in the case of dyslipidemia) is not necessarily identified. In practice, this
342	policy is so relevant that the most economically vulnerable groups could not attempt not to
343	have free medicines, at least for hypertension, diabetes and dyslipidemia.
344	
345	"Moderator: Do any of you receive these medicines from GES?

346	W: No, what is that?
347	Moderator: Do any of you receive medication through GES?
348	Several ask: What is it?
349	W: what is GES?" (FG Coyhaique, mixed, FONASA, 45 to 65 years old)
350	
351	In the case of ISAPRE beneficiaries, in general they pay directly for medications for
352	hypertension, diabetes and dyslipidemia, predominating in this group the idea that free access
353	refers to socially vulnerable groups and cared for in the primary health care network, clearly
354	appearing the concept of social class different from their own: "That class is the most
355	vulnerable".
356	
357	"M: I believe that the vast majority buy them.
358	W: You just have to buy them.
359	M: Out of your pocket.
360	M: I think there is a very small class, and that class is the one that is most vulnerable,
361	it is the one that resorts to primary health care which are the SAMU, or SAPU, I do
362	not know what they are called now.
363	M: But most I think still resort to buying them with their money, in a particular way."
364	(FG Viña del Mar, mixed, ISAPRE, 45 to 65 years old)
365	
366	For this group of beneficiaries, there is a lack of knowledge and low use of
367	GES/AUGE and the medication coverage it offers; they preferentially choose to maintain
368	freedom of purchase and their relationship with the treating doctors. In ISAPRE the
369	GES/AUGE are attended by a closed network of private providers, defined a priori by each

370	insurer, therefore, they restrict the free choice or continuity of treatment with the treating	
371	physician, before having to adapt to the GES protocols (or AUGE). The cost of medicines	
372	would be considered marginal relative to meeting the requirements of the plan enrollment.	
373	From the perception and beliefs of these users, there is a lack of information and	
374	understanding about the process of accessing GES, even some assume that they would have	
375	to pertain to the public health care system, which would be a barrier to access for these	
376	segments.	
377		
378	"Moderator: Have you made use of GES for these pathologies [diabetes,	
379	hypertension]?	
380	W: No.	
381	W: No.	
382	W: It is that my apprehension was ultimately, according to what I understand, they	
383	force you to a doctor from the Auge	
384	W: In the ISAPRE.	
385	W: Sure, and ultimately if you want to go to your doctor, you can't.	
386	M: Unless it just coincides	
387	W: Ah, but that's very difficult.	
388	W: But what you can do, for example, is go to the doctor from the Auge, to examine	
389	you, to give you the medicines, which are quite cheap, and then you tell your doctor,	
390	every so often, you know that they are giving me so much, go check.	
391	W: Ah, there you have a parallel.	
392	W: Sure." (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65 years old)	

393	In this way, the use of GES, for this group, would be justified in the case of pathologies with
394	higher cost treatments.
395	
396	"M: For the medication I take for the prostate issue, which is another issue, I do it
397	through GES.
398	W: Oh too.
399	W: Ah, but you pay nothing there.
400	M: Of course, it is a daily pill, which are 30. They cost \$45,000.
401	Moderator: \$45.000?
402	M: And if not a little more. And on the other hand, five.
403	W: Wow, I mean, I do all the management anyway.
404	W: You pay \$5,000 monthly.
405	W: What happens is that your pathology was in the GES, in the Auge, so you register,
406	that the doctor registers you for the Auge, you call the ISAPRE and the ISAPRE refers
407	you to a doctor from the Auge and you must pay that monthly 5,000." (FG Vitacura
408	– Las Condes, mixed, ISAPRE, 45 to 65 years old)
409	
410	On the other hand, it is recognized, among this group of users, that GES operates as a
411	conditional transfer, that is, the delivery of medicines requires the person to go through
412	systematic health checkups.

413

414 "M: Of course, I go every 6 months to the doctor, they examine me, they still do 415 exams, they force you to be monitoring, which is a bit the idea, because ultimately

416 people let themselves go a bit." (FG Vitacura – Las Condes, mixed, ISAPRE, 45 to 65
417 years old)

418

419 Another element that interferes with people's access to GES coverage is the role 420 played by doctors, who can act as facilitators or hinder access to GES.

421

422 "W: They do not tell you, there are doctors who do and others who do not, for 423 example, I always went to the ophthalmologist and, well, I was going for the driver's 424 license that previously took away a year for not wearing glasses, but pretentiously, 425 not anymore, so I went to the ophthalmologist, well she happily ... I, exceptional, 426 because she told me "vou know what, vou can come in one more week". Yes, I told 427 her, but why "because in five more days you turn 65 and I can give them to you through the GES", but because she proposed it to me, because otherwise I would have 428 429 had no idea". (FG Providencia -Las Condes – San Miguel, mixed, ISAPRE, over 65 430 *vears old*)

431

In general terms, beyond the differences in terms of the health subsystem to which the beneficiaries belong, and the three chronic conditions of interest (whose medicines they access either free or at low cost), in terms of affordability, the existence of a precarious balance in terms of access to medicines is recognized among the participants. The occurrence of a simple event, such as the emergence of diseases that affect other members of the family group, or other diseases with treatments not covered or of higher cost, is enough to destabilize the family budget, and often force them to prioritize.

439

W: One has a relatively easy time, but it is enough that someone gets sick, I do not
know, an illness, my daughter needed antibiotics and 50 thousand pesos an antibiotic,
more, I do not know, other things and the budget, apart from what I am taking fixed
every month, there is no budget that endures in terms of medicines. Any family can
be economically destabilized in a month with an illness, in a month. One can
overcome it, but it is in installments, you get indebted to get out of that and that's how
it is." (FG Providencia – Las Condes, mixed, FONASA and ISAPRE, 45- 65 years
old)
Finally, from the point of view of affordability, a positive assessment towards Popular
Pharmacies is also perceived.
W: I will always buy a medicine that is for osteoarthritis that in the pharmacy costs
about \$ 27,000 and here it costs 16, it is a tremendous, what is it called, savings, and
there are many people who do not know that type of help.
W: That's super important and valuable because you save a lot of money that you can
spend on food or milk, on anything, so
W: It has to say permanent prescription and has nothing to do with social class, only
medication and diagnosis. " (FG Coyhaique, mixed, FONASA, 45 to 65 years old)
Acceptability

462	FONASA beneficiaries, who receive free medicines through the network of public
463	providers, are confident that these will yield benefits for their health, and in some cases the
464	quality is even considered to have improved over time.
465	
466	"Moderator: So, about the quality and effectiveness of the medications you receive in
467	the clinic. How do you evaluate them? What do you think of the medications you are
468	given?
469	M: To me they are good.
470	W: Same.
471	W: Very good too.
472	M: Good because the doctor, although it is true, gives you the prescription and
473	everything. It's the exact thing, what's needed, the corresponding doses, everything.
474	No problem.
475	M: Yes, very good.
476	Moderator: And do you think the medications from the clinic could do any harm? Or
477	not?
478	M: No
479	Moderator: Do you trust your medications 100%?
480	M: Yes, because it has changed a lot. Before there were quite a few Chilean
481	laboratories, but much has changed. The medications have changed." (FG Arica,
482	mixed, FONASA, 45 to 65 years old)
483	
484	However, although the effectiveness of medicines for the diseases studied is not
485	questioned, in the case of Metformin the side effects are suffered, which result in additional

486 health expenses to overcome them. This situation is reported in several groups of users served487 in the public health care network.

488

489 "W: I already told you, they did X-rays, ultrasound scans, the whole story. What 490 happened: consequently, I got ulcers with metformin, apart from the fact that it is a 491 very large pill, it is very unpleasant to take it, and you must break it and the whole 492 story. Then the doctor told me, he gave me the alternative, unfortunately I cannot give 493 *you another medication because we are a polyclinic.* 494 W: Now, I started to take Metformin again, and it makes me vomit and gives me 495 diarrhea." (FG Covhaique, mixed, FONASA, 45 to 65 vears old) 496 497 On the other hand, among the ISAPRE beneficiaries, higher prices are associated with 498 greater effectiveness, perceiving a higher quality of the medicines they buy in retail 499 pharmacies, than those received by FONASA beneficiaries in the public sector. In this sense, belonging to an ISAPRE would be a guarantee of access to medicines that are considered 500 501 more expensive, but also more effective. 502 503 "Moderator: Do you think that having ISAPRE or FONASA changes access to 504 medicines? 505 W: Yes. 506 *Moderator: Why, how?* 507 W: Because the doctor, in fact, you see, can give him or herself a greater luxury of 508 giving you better qualities medications, of not being in an ISAPRE because, for

509 *example, you go to the clinic, and they give you the cheapest medications there are...*

510	W: The	generics.
-----	--------	-----------

W: That is, generics, which supposedly they say are not the same quality as
medications that have a name or a pharmacy, that is, from a better laboratory, I do
not know, it has always been said. " (FG Providencia – Las Condes – San Miguel,
ISAPRE, over 65 years old)
Finally, ISAPRE users express greater reluctance to use bioequivalent medicines,

with suspicion predominating in their discourse about the effectiveness and quality of generic and bioequivalent medications. This articulates some beliefs and opinions based on own experiences of use: that they work like placebos, that doses must be increased to reach the effectiveness of a brand-name drug, that the savings may be less if doses are increased.

521

"W: They are not the same either, one can notice it even in terms of sensations, in the
basics, paracetamol for headache, you have the generic, the bioequivalent and the
name brand and with the last two your headache goes away and the other, you have
to take 3 or 4 pills and in the end what is the generic for if it does not work for you, if
it doesn't give you the result. You say, I spent two more coins or two less coins, but in
the end, as I took more, the generic came out more expensive." (FG Providencia –
Las Condes, mixed, FONASA and ISAPRE, 45- 65 years old)

529

530 Adaptation

532	In general, people served in the public network evaluate that the dynamics of
533	medication provision is in line with their possibilities. Medicine pickup is a regular activity
534	that people carry out every month and that keeps them in contact with the health care system.
535	The extensive territorial network of health facilities addresses the issue of physical distance
536	being accessible to users.
537	
538	"Moderator: And how often, how many times How often do you actually go to the
539	clinic to get your medication?
540	W: Every month.
541	M: Each month.
542	W: Every month.
543	W: Every month we have a day.
544	Moderator: So how difficult is it for you to access these medications?
545	M: It's easy for me.
546	W: No, it's not difficult." (FG Arica, mixed, FONASA, 45 to 65 years old)
547	
548	The logistics of medicine provision is one of the most recognized aspects of primary
549	care; there are significant improvements in terms of access and treatment, and it introduces
550	a differentiation between public clinics and hospitals, where the latter represent the most
551	critical face of the public health system.
552	
553	The adaptation is lower in very particular cases that are referred to groups, such as
554	people who live alone and have lost autonomy, older adults with disabilities or people living
555	in isolated places, these segments can evaluate their access possibilities as restricted.

556)
-----	---

557	"M: But in general, the great majority of people are very few who are isolated, very
558	few, the great majority have good services." (FG Coyhaique, mixed, FONASA, 45 to
559	65 years old)
560	
561	"W: One has to remember to go to pick up the medications, if not, he or she loses
562	them, that's where I tell him about the elderly, let's say, there are old people who are
563	not they are old, and they cannot come to pick them up, they have no young person
564	to send" (FG Pelarco, FONASA, 45 to 65 years old)
565	
566	FONASA and ISAPRE differences
567	
568	Figures 1 and 2 present the empathy maps associated with the FONASA and ISAPRE
569	beneficiaries, respectively.
570	
571	According to that presented in Figure 1, it is possible to note that FONASA
572	beneficiaries, despite their greater socio-economic vulnerability, perceive greater protection
573	in access to their medicines. Access conditions, delivery regularity and adherence to
574	pharmacological treatment are met. For this group, the treatment financing for comorbidities
575	and morbidities of the family group is perceived as the main problem.
576	
577	Figure 1. FONASA Beneficiary Empathy Map
578	

579	On the other hand, users in the public sector value the territorial coverage of primary
580	care, which guarantees access in isolated areas. Regarding the type of provider, the public
581	sector shows greater capacity for loyalty of users, which is expressed in regular check-ups
582	and feeling of monitoring; unlike more irregular visits among beneficiaries of the private
583	sector.
584	
585	As observed in Figure 2, private sector policyholders, for their part, understand that
586	they have access to better quality medicines than those provided free of charge by the public
587	sector. However, they report fears associated with inability to afford them and greater distrust
588	in the process, linked to alliances between laboratories and physicians.
589	
590	Figure 2. ISAPRE Beneficiary Empathy Map
591	
592	Discussion

593

594 The findings of the present study characterize the access to medicines in Chile of 595 people of different socioeconomic conditions and residents in scattered regions of the 596 country, for the three chronic conditions of interest: hypertension, diabetes and dyslipidemia. 597 As mentioned in the introductory section, these three non-communicable conditions have a 598 high prevalence in Chile and, from the point of view of coverage by the health system, they 599 have been prioritized, through the Explicit Health Guarantees – GES, for the FONASA and 600 ISAPRE beneficiaries, and the Primary Health Care Pharmacy Fund, for the FONASA 601 beneficiaries (20).

602

The high segmentation of the Chilean health system, the geographical extension of the country, as well as the existence of rural and isolated areas throughout the territory significantly determine the way Chileans access their medicines, as well as the barriers they must face, and the facilitators they have in the process.

607

The provision of medicines is affected by variables in the organization of health services. It is noteworthy that primary care has succeeded in establishing coordination and monitoring of the population caring for, at least for chronic diseases, which would favor the control of these diseases.

612

613 The above explains that, in general terms, people affiliated with FONASA have 614 access to medicines for the treatment of the diagnoses studied through the institutional public 615 health network, free of charge because of public policies that include: Explicit Health 616 Guarantees (GES or AUGE) and Pharmacy Fund (FOFAR). For their part, the people 617 affiliated with ISAPRE mostly access medications through direct purchase in pharmacies and 618 pay for the entire treatment, which is considered an insignificant expense due to the low cost 619 of these in the case of the three conditions studied. This segment can also access the GES; 620 however, a marginal use of guarantees was observed associated with administrative barriers, 621 ignorance and resistance to attend the preferential network of ISAPRE for the GES, which 622 implies changing the treating physician.

623

624 In general terms, there are no relevant barriers in the case of medicines for the three 625 conditions of interest for FONASA beneficiaries. However, access barriers for other

626 medications are identified and these are associated, in the case of public sector beneficiaries, 627 with out-of-pocket spending on medicines not covered or not prioritized by the health system 628 and, in those cases where the medicines are covered but circumstantially encounter stock 629 shortages in public establishments, the availability barrier appears, with the consequent 630 affordability problems associated with having to purchase them in retail. The facilitators, for 631 their part, include policies and programs that establish medication coverage and guarantee 632 availability and financial protection; the territorial deployment of primary care in the country; 633 and the acceptance and assessment by FONASA users of the public sector care model, which 634 determines the control and permanent contact of users with the health system.

635

636 In the case of private sector beneficiaries who, as mentioned, buy mainly in retail, 637 significantly associating the price of quality medications; one of the barriers identified is 638 adaptation, and has to do with the non-acceptance or rejection by users of retail practices 639 (lack of transparency, collusion, etc.), which in turn is related to the out-of-pocket expenses 640 they must incur. In the case of these beneficiaries, another adaptation barrier also emerges, 641 associated with the lack of knowledge of the processes for obtaining the benefits delivered 642 by the GES, and another of acceptability, related to the rejection of the conditions imposed 643 for obtaining them (e.g., bureaucracy, renunciation of free choice, use of generics). Among 644 the facilitators for the ISAPRE users, there is the budget availability that, in general, allows 645 them to pay for the required medicines, at least for the three chronic conditions of interest for 646 the analysis, the potential lower out-of-pocket expenditure to be able to access through the 647 GES, and the possibility of having complementary coverage through voluntary insurance.

648

649 It is worth mentioning that the eruption of popular or municipal pharmacies is an 650 access facilitator recognized by users in a transversal way, allowing access to lower prices 651 compared to retail.

652

653 The results presented here are in line with findings published in the literature, first, 654 regarding the relevance, as a facilitator for access to medicines, of having coverage or health 655 insurance, from the point of view of out-of-pocket spending and affordability, and as a barrier 656 if this possibility is not available. It is possible to find experiences of countries in different 657 economic or geographical contexts in this regard (21-24). In fact, in the Americas region, 658 there are close examples, such as the case of Brazil with the free delivery of medications by 659 the SUS, and its Health Has no Price programs (for hypertension and diabetes as is of interest 660 in this research) and Popular Pharmacies (25–28). Another barrier that emerges in the study 661 and is also reported in the literature for various countries, such as Barbados, the US and 662 Colombia, relates to the bureaucracy or how complex and cumbersome it is to understand 663 the insurance requirements to obtain medication coverage (29-31), as happens in Chile to the 664 ISAPRE beneficiaries for the use of GES.

665

One of the main limitations of this study is related to the conduct of group interviews during the Covid-19 pandemic, which, among others, required strict monitoring of protocols, and also made it necessary to address, within the framework of the interviews, some issues related to access to medication during the pandemic, and then further examine (removing the focus of the pandemic) more general issues associated with this access. However, this limitation became, in turn, an opportunity to explore people's perceptions about access to

672 medicines in the pandemic context, and the ways in which the Chilean health system673 addressed this problem in this period of greatest difficulties.

674

675 Finally, within the framework of this research it was possible to identify opportunities 676 for improvement for public health policy, among the main ones, and in line with the 677 aforementioned, is the importance of moving towards comprehensive medicine coverage, as 678 well as its free delivery by health systems to achieve better and more equitable access. 679 Another implication relates to the need to strengthen, on the part of the health authority, the 680 messages around the quality of bioequivalents, to increase the confidence of users in the 681 policies of access to generics, which are delivered free of charge by the system. Finally, it is 682 necessary to inform the population about how to access the benefits of policies or programs, 683 and to make the relationship between gratuity and these policies transparent, as part of the 684 State's commitment to advancing the rights of access to health.

685

686 Acknowledgements

687

The authors thank the financing of the FONIS SA19|0174 Project, granted by the
National Agency for Research and Development, Chile (ANID), in the framework of which
this study was carried out.

691

692 The authors also thank the fieldwork team for their support in conducting the 693 interviews.

- Finally, we thank all the participants in the interviews conducted for sharing theirtime and experiences.
- 697

698 **References**

- 1. Levesque J-F, Harris M, Russell G. Patient-centred access to health care:
- 700 conceptualising access at the interface of health systems and populations. Int J
- 701 Equity Health. 2013;12(18):1–9.
- 2. Koh JJK, Cheng RX, Yap Y, Haldane V, Tan YG, Teo KWQ, et al. Access and
- adherence to medications for the primary and secondary prevention of
- atherosclerotic cardiovascular disease in singapore: A qualitative study. Patient
- 705 Prefer Adherence. 2018;12:2481–98.
- Tanahashi T. Health service coverage and its evaluation. Bull World Health Organ.
 1978;56(2):295–303.
- Penchansky R, Thomas JW. The Concept of Access : Definition and Relationship to
 Consumer Satisfaction. Med Care. 1981;19(2):127–40.
- 5. Castillo-Laborde C, Hirmas-Adauy M, Matute I, Jasmen A, Urrejola O, Molina X, et
- al. Barriers and Facilitators in Access to Diabetes, Hypertension, and Dyslipidemia
- 712 Medicines: A Scoping Review. Public Health Rev. 2022;43(September):1–18.
- 713 6. Organización Mundial de la Salud. Acceso equitativo a los medicamentos esenciales:
 714 un marco para la acción colectiva. 2004.
- 715 7. Ministerio de Salud. Encuesta Nacional de Salud 2016-2017. Uso de medicamentos.716 2018.
- 717 8. Ministerio de Desarrollo Social. Salud. Síntesis de Resultados Encuesta CASEN

718	2017 [Internet].	2018.	Available from:
-----	--------	------------	-------	-----------------

- 719 http://observatorio.ministeriodesarrollosocial.gob.cl/casen-
- 720 multidimensional/casen/docs/Resultados_Salud_casen_2017.pdf
- 9. Bruzzo S, Henríquez J, Velasco C. Radiografía del gasto de bolsillo en salud en
- 722 Chile: una mirada desagregada. Vol. 478, Puntos de Referencia, Centro de Estudios
- 723 Públicos. 2018.
- 10. Ministerio de Salud. Encuesta uso racional de medicamentos. Informe Final. 2011.
- 11. Universidad San Sebastián. Encuesta Consumo de Medicamentos. 2017.
- 12. Castillo-Laborde C, Aguilera-Sanhueza X, Hirmas-Adauy M, Matute I, Delgado-
- Becerra I, Ferrari MN-D, et al. Health Insurance Scheme Performance and Effects on
- Health and Health Inequalities in Chile. MEDICC Rev. 2017;19:57–64.
- 13. Castillo-Laborde C, Matute Willemsen I, Aguilera-Sanhueza X. Introducción. In:
- Castillo-Laborde C, Matute Willemsen I, Aguilera-Sanhueza X, editors. La Ruta del
 Medicamento en Chile. 2022. p. 15–23.
- 732 14. Ministerio de Salud. Ley 19966. Establece un Régimen de Garantías Explícitas.
 733 2004.
- Ministerio de Salud. Fondo de Farmacia. FOFAR. [Internet]. 2018 [cited 2018 Dec
 17]. Available from: https://www.minsal.cl/fofar/
- 16. Ministerio de Desarrollo Social y Familia. Estimaciones de Tasas de Pobreza por
- 737 ingresos y Multidimensional por Comunas [Internet]. Observatorio Social; 2017.
- 738 Available from:
- 739 http://observatorio.ministeriodesarrollosocial.gob.cl/storage/docs/pobreza-
- 740 comunal/2017/PLANILLA_Estimaciones_comunales_tasa_pobreza_por_ingresos_
- 741 multidimensional_2017.xlsx

742	17.	ATLAS.ti Scientific Software Development GmbH. Atlas.ti. Version 9.1.2. 2021.
-----	-----	---

- 18. Iglesias Y. El Mapa de Empatía [Internet]. 2017 [cited 2022 Apr 18]. Available
- from: https://designthinking.gal/el-mapa-de-empatia/
- 19. Ministerio de Salud. Recomendaciones para Farmacias Populares: Orientaciones en
- 746 Abastecimiento, Vinculación con la Atención Primaria en Salud y Uso Racional de
- 747 Medicamentos [Internet]. Santiago, Chile; 2018. Available from:
- 748 https://www.minsal.cl/wp-content/uploads/2015/09/Recomendaciones-Farmacias-
- 749 Populares.pdf
- 750 20. Hirmas Adauy M, Awad Avendaño C. Modalidades de acceso a los medicamentos
- 751 por parte de los pacientes. In: Castillo-Laborde C, Matute-Willemsen I, Aguilera-

Sanhueza X, editors. La Ruta del Medicamento en Chile. 2022. p. 1–114.

753 21. Tjia J, JS S. Will the Medicare prescription drug benefit eliminate cost barriers for

older adults with diabetes mellitus? J Am Geriatr Soc [Internet]. 2006

- 755 Apr;54(4):606–12. Available from:
- http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=106314266&lang
 =es
- Vialle-Valentin CE, Serumaga B, Wagner AK, Ross-Degnan D. Evidence on access
 to medicines for chronic diseases from household surveys in five low- and middle-
- income countries. Health Policy Plan. 2015;30(8):1044–52.
- Beran D. The Impact of Health Systems on Diabetes Care in Low and Lower Middle
 Income Countries. Curr Diab Rep [Internet]. 2015 Apr 28;15(4):20. Available from:
- 763 http://link.springer.com/10.1007/s11892-015-0591-8
- 764 24. Naheed A, Haldane V, Jafar TH, Chakma N, Legido-Quigley H. Patient pathways
- and perceptions of hypertension treatment, management, and control in rural

766		Bangladesh: a qualitative study. Patient Prefer Adherence [Internet]. 2018
767		Aug;Volume 12:1437-49. Available from: https://www.dovepress.com/patient-
768		pathways-and-perceptions-of-hypertension-treatment-managementpeer-reviewed-
769		article-PPA
770	25.	Araujo JLO, Pereira MD, de Sá Del Fiol F, Barberato-Filho S. Access to
771		Antihypertensive Agents in Brazil: Evaluation of the "Health Has No Price"
772		Program. Clin Ther [Internet]. 2014 Aug;36(8):1191-5. Available from:
773		https://linkinghub.elsevier.com/retrieve/pii/S0149291814003592
774	26.	Araujo JLO, Pereira MD, de Cássia Bergamaschi C, de Sá Del Fiol F, Lopes LC, de
775		Toledo MI, et al. Access to medicines for diabetes treatment in Brazil: evaluation of
776		"health has no price" program. Diabetol Metab Syndr [Internet]. 2016 Dec
777		10;8(1):35. Available from:
778		http://dmsjournal.biomedcentral.com/articles/10.1186/s13098-016-0150-8
779	27.	Emmerick ICM, Campos MR, Luiza VL, Chaves LA, Bertoldi AD, Ross-Degnan D.
780		Retrospective interrupted time series examining hypertension and diabetes medicines
781		usage following changes in patient cost sharing in the "Farmácia Popular"
782		programme in Brazil. BMJ Open [Internet]. 2017 Nov 3;7(11):e017308. Available
783		from: https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2017-017308
784	28.	Fritzen JS, Motter FR, Paniz VMV. Regular access and adherence to medications of
785		the specialized component of pharmaceutical services. Rev Saude Publica [Internet].
786		2017 Nov 27;51:109. Available from:
787		https://www.revistas.usp.br/rsp/article/view/140988
788	29.	Legido-Quigley H, Camacho Lopez PA, Balabanova D, Perel P, Lopez-Jaramillo P,
789		Nieuwlaat R, et al. Patients' Knowledge, Attitudes, Behaviour and Health Care

- 790 Experiences on the Prevention, Detection, Management and Control of Hypertension
- in Colombia: A Qualitative Study. Barengo NC, editor. PLoS One [Internet]. 2015
- 792 Apr 24;10(4):e0122112. Available from:
- 793 https://dx.plos.org/10.1371/journal.pone.0122112
- 30. Adams OP, Carter AO. Diabetes and hypertension guidelines and the primary health
- 795 care practitioner in Barbados: knowledge, attitudes, practices and barriers--a focus
- group study. BMC Fam Pract [Internet]. 2010 Jan;11:9p–9p. Available from:
- 797 http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=105003843&lang
- 798 =es
- 31. Suraci C, Mulas F, Rossi MC, Gentile S, Giorda CB. Management of newly
- 800 diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A
- 801 SUBITO!AMD survey on the early diabetes treatment in Italy. Acta Diabetol.

802 2012;49(6):429–33.

Figure 1. FONASA Beneficiary Empathy Map



the public network; budget deficit to cover treatments; price increases of medications in general; the arbitrariness of the market to fix prices. » Obstacles overcome: the capacity of available resources in the public network is perceived as incremental.



Figure 2. ISAPRE Beneficiary Empathy Map